RAD51 protein is a predictor of chemosensitivity and survival prognosis in patients with advanced high-grade serous ovarian cancer undergoing neoadjuvant chemotherapy

ObjectiveThe primary aim of this study is to investigate the relationship between the expression of the homologous recombination protein RAD51 and the CA125 elimination rate constant K (KELIM) score in the context of sensitivity to neoadjuvant chemotherapy (NACT) in patients with advanced high-grade...

Full description

Bibliographic Details
Published in:	Frontiers in Oncology
Main Authors:	Hui Liu, Yufang Xia, Yunqing Chen, Huiyang Qi, Huixiang Ji, Shujun Ji, Yanhui Lou
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2025-10-01
Subjects:	RAD51 protein KELIM score high-grade serous ovarian cancer neoadjuvant chemotherapy chemotherapy sensitivity
Online Access:	https://www.frontiersin.org/articles/10.3389/fonc.2025.1548889/full

Similar Items

The impact of RAD51 protein on the sensitivity of ovarian cancer to neoadjuvant chemotherapy
by: LIU Hui, CHEN Yunqing, QI Huiyang, SUN Xin, LOU Yanhui
Published: (2025-08-01)

Major pathologic response and RAD51 predict survival in lung cancer patients receiving neoadjuvant chemotherapy
by: Apar Pataer, et al.
Published: (2018-06-01)

RAD51 wrestles with SUMO
by: Younghoon Kee, et al.
Published: (2022-12-01)

Hot on RAD51C: structure and functions of RAD51C‐XRCC3
by: Barnabas Szakal, et al.
Published: (2023-10-01)

RAD51 as a biomarker for homologous recombination deficiency in high‐grade serous ovarian carcinoma: robustness and interobserver variability of the RAD51 test
by: Claire JH Kramer, et al.
Published: (2023-11-01)

Neoadjuvant chemotherapy in patients with stage IVB uterine serous carcinoma: a Turkish multicentric study
by: Mehmet Unsal, et al.
Published: (2023-12-01)

Melanoma cells replicate through chemotherapy by reducing levels of key homologous recombination protein RAD51 and increasing expression of translesion synthesis DNA polymerase ζ
by: Liang Song, et al.
Published: (2017-12-01)

New prognostic index for neoadjuvant chemotherapy outcome in patients with advanced high-grade serous ovarian cancer
by: Chuying Huo, et al.
Published: (2024-12-01)

Neoadjuvant chemotherapy induces phenotypic mast cell changes in high grade serous ovarian cancer
by: Julia McAdams, et al.
Published: (2024-09-01)

RAD51 is a poor prognostic marker and a potential therapeutic target for oral squamous cell carcinoma
by: Yu-Fen Tsai, et al.
Published: (2023-10-01)

Neutrophil–Lymphocyte Ratio and KELIM Score as Prognostic Markers in High-Grade Serous Advanced Ovarian Cancer Patients Treated with Neoadjuvant Chemotherapy
by: Vasilis Theodoulidis, et al.
Published: (2025-04-01)

Rad52-Rad51 association is essential to protect Rad51 filaments against Srs2, but facultative for filament formation
by: Emilie Ma, et al.
Published: (2018-07-01)

BRIP1, RAD51C, and RAD51D mutations are associated with high susceptibility to ovarian cancer: mutation prevalence and precise risk estimates based on a pooled analysis of ~30,000 cases
by: Malwina Suszynska, et al.
Published: (2020-05-01)

RAD51 expression and prognostic impact in patients with stomach adenocarcinoma
by: Baiyu Jian, et al.
Published: (2025-04-01)

Knocking down RAD51AP1 enhances chemosensitivity by inhibiting the self-renewal of CD133 positive ovarian cancer stem-like cells
by: Si-heng Zeng, et al.
Published: (2024-09-01)

On the role of AtDMC1, AtRAD51 and its paralogs during Arabidopsis meiosis
by: Mónica ePradillo, et al.
Published: (2014-02-01)

CA-125 elimination rate constant K (KELIM) as a promising predictor of complete cytoreduction after neoadjuvant chemotherapy in advanced ovarian cancer patients: a retrospective study from two Chinese hospitals
by: Cheng Li, et al.
Published: (2024-05-01)

Conserved architecture of RAD51 recombinase in ruminants revealed through molecular cloning and characterization
by: SONIKA AHLAWAT, et al.
Published: (2016-12-01)

Comprehensive Analysis of the Expression and Prognosis for RAD51 Family in Human Breast Cancer
by: Shi Y, et al.
Published: (2022-05-01)

Molecular Determinant of DIDS Analogs Targeting RAD51 Activity
by: Denis Velic, et al.
Published: (2021-09-01)

Rad52 Oligomeric N-Terminal Domain Stabilizes Rad51 Nucleoprotein Filaments and Contributes to Their Protection against Srs2
by: Emilie Ma, et al.
Published: (2021-06-01)

Expanding the Editing Window of Cytidine Base Editors With the Rad51 DNA-Binding Domain in Rice
by: Chunjie Wei, et al.
Published: (2022-04-01)

The Anticancer Effect of RAD51-IN-1 in MDAH-2774 (CVCL_0420) Cells
by: Deniz ÖZDEMİR, et al.
Published: (2025-04-01)

Bleomycin induces senescence and repression of DNA repair via downregulation of Rad51
by: Fuqiang Chen, et al.
Published: (2024-04-01)

ATM Promotes RAD51-Mediated Meiotic DSB Repair by Inter-Sister-Chromatid Recombination in Arabidopsis
by: Yuan Yao, et al.
Published: (2020-06-01)

Research Advances of RAD51AP1 in Tumor Progression and Drug Resistance
by: Renwang LIU, et al.
Published: (2023-09-01)

A novel small molecule RAD51 inactivator overcomes imatinib‐resistance in chronic myeloid leukaemia
by: Jiewen Zhu, et al.
Published: (2013-01-01)

Structural mechanism of strand exchange by the RAD51 filament
by: Luay Joudeh, et al.
Published: (2025-08-01)

RAD51 modulates in nasopharyngeal carcinoma cells by regulating Caspase-8-mediated pyroptosis
by: Fuchuan Xie, et al.
Published: (2025-07-01)

Redox regulation of RAD51 Cys319 and homologous recombination by peroxiredoxin 1
by: John J. Skoko, et al.
Published: (2022-10-01)

Expression and Prognostic Value of RAD51 in Adenocarcinoma at the Gastroesophageal Junction
by: Darebai Redati, et al.
Published: (2022-10-01)

Identification of a RAD51B enhancer variant for susceptibility and progression to glioma
by: Liming Huang, et al.
Published: (2023-10-01)

The Emerging Roles of Rad51 in Cancer and Its Potential as a Therapeutic Target
by: Ziyi Wang, et al.
Published: (2022-07-01)

Clinicopathological and Prognostic Characteristics of RAD51 in Colorectal Cancer
by: Jae-Ho Lee, et al.
Published: (2020-01-01)

Neoadjuvant and Adjuvant Chemotherapy in Osteosarcoma (The Experience of HORC in the Shariati Hospital)
by: Alimoghadam K, et al.
Published: (2004-07-01)

Association between polymorphisms in MicroRNA target sites of RAD51D genes and risk of hepatocellular carcinoma
by: Yan‐Ji Jiang, et al.
Published: (2019-05-01)

RAD51 as an immunohistochemistry-based marker of poly(ADP-ribose) polymerase inhibitor resistance in ovarian cancer
by: Yoo-Na Kim, et al.
Published: (2024-04-01)

Sequence analysis of the DNA-repair gene rad51 in the tardigrades Milnesium cf. tardigradum, Hypsibius dujardini and Macrobiotus cf. harmsworthi
by: Eliana A. Beltrán-Pardo, et al.
Published: (2013-05-01)

Quantitative imaging of RAD51 expression as a marker of platinum resistance in ovarian cancer
by: Michal M Hoppe, et al.
Published: (2021-03-01)

Metastatic Serous Carcinoma of the Testis: A Case Report and Review of the Literature
by: Yuk Ting Ma, et al.
Published: (2011-04-01)